Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GH Guardant Health Inc.

Closed 06-25 16:00:00 EDT

142.94

+5.98

+4.37%

盘后145.60

+2.66+1.86%

19:59 EDT

High145.84	Low137.50	Vol2.55M
Open137.85	D1 Closing136.96	Amplitude6.09%
Mkt Cap18.95B	Tradable Cap18.15B	Total Shares132.57M
T/O363.58M	T/O Rate2.01%	Tradable Shares127.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GH","market":"US","secType":"STK","nameCN":"Guardant Health Inc.","latestPrice":142.94,"timestamp":1782417600000,"preClose":136.96,"halted":0,"volume":2547280,"hourTrading":{"tag":"盘后","latestPrice":145.6,"preClose":142.94,"latestTime":"19:59 EDT","volume":44711,"amount":6397068.4024,"timestamp":1782431994161,"change":2.66,"changeRate":0.018609,"amplitude":0.021408},"delay":0,"changeRate":0.04366238317757001,"floatShares":127000000,"shares":132573424,"eps":-3.404949,"marketStatus":"Closed","change":5.98,"latestTime":"06-25 16:00:00 EDT","open":137.85,"high":145.84,"low":137.5,"amount":363582113.4616,"amplitude":0.060894,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.404949,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782460800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":136.96,"preHourTrading":{"tag":"盘前","latestPrice":138,"preClose":136.96,"latestTime":"09:29 EDT","volume":2169,"amount":302464.16523,"timestamp":1782394166037,"change":1.04,"changeRate":0.007593,"amplitude":0.021174},"postHourTrading":{"tag":"盘后","latestPrice":145.6,"preClose":142.94,"latestTime":"19:59 EDT","volume":44711,"amount":6397068.4024,"timestamp":1782431994161,"change":2.66,"changeRate":0.018609,"amplitude":0.021408},"volumeRatio":0.998019,"impliedVol":0.5776,"impliedVolPercentile":0.3068},"requestUrl":"/m/hq/s/GH/wiki","defaultTab":"wiki","newsList":[{"id":"1159506789","title":"Movement Alert｜Guardant Health Rises 5.05% in Regular Trading, Multiple Catalysts Drive Continued Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1159506789","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159506789?lang=en_us&edition=fundamental","pubTime":"2026-06-25 22:31","pubTimestamp":1782397901,"startTime":"0","endTime":"0","summary":"On June 25, Guardant Health rose 5.05% in regular trading, trading at 143.47 USD/share, with turnover of $79.42 million. The stock continued its upward momentum driven by a convergence of positive...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645811531","title":"Guardant Health is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2645811531","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645811531?lang=en_us&edition=fundamental","pubTime":"2026-06-24 22:47","pubTimestamp":1782312420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings(END) Dow Jones NewswiresJune 24, 2026 10:47 ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0889565916.HKD","BK4535","BK4196","GH","LU0320765992.SGD","BK4585","BK4551","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645821896","title":"Guardant Health price target raised to $150 from $120 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2645821896","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645821896?lang=en_us&edition=fundamental","pubTime":"2026-06-24 16:55","pubTimestamp":1782291346,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Guardant Health (GH) to $150 from $120 and keeps an Overweight rating on the shares. The firm adjusted t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-150-from-120-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-150-from-120-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4551","BK4585","BK4196","GH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645854206","title":"Guardant Health director Myrtle S. Potter disposes of 1,556 common shares worth $204,084.96","url":"https://stock-news.laohu8.com/highlight/detail?id=2645854206","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645854206?lang=en_us&edition=fundamental","pubTime":"2026-06-24 05:29","pubTimestamp":1782250163,"startTime":"0","endTime":"0","summary":"Guardant Health director Myrtle S. Potter sold 1,556 common shares on June 22, 2026 at USD 131.16.Potter held 20,971 common shares following the sale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL9jsQJm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health director Myrtle S. Potter disposes of 1,556 common shares worth $204,084.96","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4585","BK4535","BK4551","BK4588","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645883025","title":"Hikma joins Guardant Health as platinum sponsor at UAE International Oncology Forum IOF 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645883025","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645883025?lang=en_us&edition=fundamental","pubTime":"2026-06-22 17:57","pubTimestamp":1782122238,"startTime":"0","endTime":"0","summary":"Hikma attended the 5th Annual International Oncology Forum IOF 2026 in the UAE as a platinum sponsor alongside Guardant Health.Hikma highlighted FDA clearance of Guardant360 Liquid CDx, positioning it to expand precision oncology diagnostics across MENA under its 2024 exclusive deal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hikma Pharmaceuticals plc published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLb4S7kY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4588","HIK.UK","IE00B0JY6N72.USD","BK4585","BK4551","BK4196","BK5011","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644361930","title":"Guardant Health shareholders elect directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2644361930","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644361930?lang=en_us&edition=fundamental","pubTime":"2026-06-19 04:12","pubTimestamp":1781813535,"startTime":"0","endTime":"0","summary":"Guardant Health held its annual shareholder meeting on June 17, 2026.An advisory resolution on executive pay failed to pass.Investors supported holding future advisory votes on executive pay every year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL12RmWC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GH","BK4551","BK4196","BK4585","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644380030","title":"Living Longer Is Big Business. These Stocks Will Benefit. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2644380030","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644380030?lang=en_us&edition=fundamental","pubTime":"2026-06-19 02:15","pubTimestamp":1781806500,"startTime":"0","endTime":"0","summary":"Health is wealth goes the saying. Now it's an investment opportunity, too.The consumerization of healthcare is nothing new, but the pandemic turbocharged its widespread adoption. From telehealth appointments to digital patient portals and wearable trackers, many people began to treat their health like any other retail experience -- whether it's walking into a CVS Health MinuteClinic after doing some shopping, or trying  to estimate the out-of-pocket price for procedures with cost-estimator tools.The upshot is that longevity, i.e. not only living longer but being healthy for longer, could be big business for healthcare companies. TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion, with beneficiaries spanning companies making biological breakthroughs to those using artificial intelligence.\"Tools to measure and screen health status--across blood-based testing, imaging, and wearable--have advanced meaningfully,\" writes lead analyst Da","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004303.SGD","LU1983299246.USD","IE00B7SZLL34.SGD","GB00BDT5M118.USD","LU2468319806.SGD","IE00BJT1NW94.SGD","LU1057294990.SGD","LU2433249047.HKD","MYGN","LU1064131342.USD","DXCM","ABT","BK4581","LU2065170008.USD","LU0345770993.USD","IE00BZ1G4Q59.USD","PLNT","CVS","LU2211815571.USD","LU1861558580.USD","LU2125909593.SGD","CAVA","IE00B2B36J28.USD","LU2065731478.USD","LU1923622614.USD","LU1989763690.USD","LU0012050646.USD","LU2133065610.SGD","LU0289739699.SGD","LU0053671581.USD","BK4568","LU2237957902.USD","SGXZ23171101.USD","BK4121","LU0208291251.USD","LU1023059063.AUD","LU0320765489.SGD","LU2125909247.SGD","HIYY","LU2065171402.SGD","GH","IE00BSNM7G36.USD","BK4588","BK4209","BTMD","IE00BKVL7J92.USD","IE0002270589.USD","BK4535","LU0162691827.USD","IE00B19Z3B42.SGD","LU2264538146.SGD","LU1721429402.USD","LU0114720955.EUR","LU0963586101.USD","LU2112291526.USD","LU2210149790.SGD","BK4548","IE00BFTCPJ56.SGD","LU1571399168.USD","BK4566","LU1061106388.HKD","LU2095319765.USD","BK4504","BK4139","LU1914381329.SGD","LU0072461881.USD","LU2324357040.USD","TDOC","LU2089984988.USD","LU0882574055.USD","LU0211331839.USD","LU0170899867.USD","BK4007","SG9999002224.SGD","SG9999002232.USD","BFLY","BK4216","IE00B19Z3581.USD","BK4082","BK4592","LU0106261612.USD","OWLT","IE00BJJMRZ35.SGD","NTRA","LU0122379950.USD","LU0390134368.USD","IE00BMPRXN33.USD","BK4196","LU0006061336.USD","LU1699723380.USD","LU0354030511.USD","IE0002141913.USD","SGXZ41872573.SGD","BK4550","BK4167","IE00BMPRXR70.SGD","LU1059921491.USD","LU2210150020.SGD","LU0432979614.USD","LU2065169927.USD","BK4585","LU0070302665.USD","LU1721429741.USD","LU2237957811.SGD","LU0058720904.USD","IE0009355771.USD","HIMY","LU0234572021.USD","LU2065171311.SGD","HIMZ","LU1989763427.SGD","BK4567","QTRX","BK4533","HMYY","BK4551","IE00B4R5TH58.HKD","LU0266013472.USD","LU1861559042.SGD","LU0345770308.USD","BK4534","HIMS","LU0061475181.USD","LU0354030438.USD","LU0868494617.USD","LU1323610961.USD","LU1691799644.USD","LU1988902786.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644727716","title":"What GH Research (GHRS)'s Phase 2a Postpartum Depression Breakthrough Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2644727716","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644727716?lang=en_us&edition=fundamental","pubTime":"2026-06-18 06:24","pubTimestamp":1781735050,"startTime":"0","endTime":"0","summary":"Earlier in June 2026, GH Research PLC reported full Phase 2a results for its inhaled Mebufotenin (GH001) in postpartum depression, showing rapid remission in all 10 patients, improved maternal functioning, and a favorable safety profile, with findings published in The Journal of Clinical Psychiatry and highlighted at the upcoming CINP 2026 congress.\nAn additional practical insight from the trial was that drug levels in breast milk supported only a brief interruption of breastfeeding around...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/what-gh-research-ghrss-phase-2a-postpartum-depression-breakt","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/what-gh-research-ghrss-phase-2a-postpartum-depression-breakt","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","BK4588","GH","BK4196","BK4535","GHRS","BK4585","BK4551","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644748410","title":"Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BridgeBio Pharma (BBIO) and Guardant Health (GH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644748410","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644748410?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:50","pubTimestamp":1781693443,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on IQVIA Holdings (IQV), BridgeBio Pharma (BBIO) and Guardant Health...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-iqvia-holdings-iqv-bridgebio-pharma-bbio-and-guardant-health-gh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-iqvia-holdings-iqv-bridgebio-pharma-bbio-and-guardant-health-gh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","HCSG","LU0128526141.USD","XLV","BK4139","LU1201861165.SGD","BK4137","BK4196","BK4588","LU0198837287.USD","LU1791710400.SGD","LU1989764664.SGD","LU1989764748.USD","BK4505","LU1791710582.SGD","BK4530","LU0477156797.USD","LABU","LU0648001328.SGD","LU1201861249.SGD","LU0528227936.USD","LU0648000940.SGD","LU0130102774.USD","BK4121","BK4581","BK4585","BK4535","BBIO","LU0980610538.SGD","GH","LU0130103400.USD","LU0477156953.USD","LU0882574055.USD","LU0130518102.USD","LU0130517989.USD","LU1261432733.SGD","LU0029874061.USD","IQV","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644715008","title":"U.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, Welltower","url":"https://stock-news.laohu8.com/highlight/detail?id=2644715008","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644715008?lang=en_us&edition=fundamental","pubTime":"2026-06-17 15:16","pubTimestamp":1781680605,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, WelltowerJune 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nL4N42P0H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","R","JAN","HR","FIGG","IONS","SBRA","ARWR","VTR","DDOG","GRDN","CTSH","HUMA","OHI","CTRE","KMB","XRN","LRCX","DOC","CAT","CNK","FDX","GKOS","MATX","LU2360032135.SGD","DOGD","AIZ","LU2298064838.USD","HUN","LU0011850046.USD","KLAG","CF","CMI","CRI","FIG","KLAC","LRCU","LU2065731478.USD","LDOS","WELL","AMAT","AMH","LU0158827781.USD","INVH","SNDR","VMI","COAG","LSTR","JBHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644797034","title":"Guardant Health Inc : Jefferies Raises Target Price to $150 From $130","url":"https://stock-news.laohu8.com/highlight/detail?id=2644797034","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644797034?lang=en_us&edition=fundamental","pubTime":"2026-06-17 12:00","pubTimestamp":1781668839,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nFWN42O0SJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","GH","BK4551","BK4535","BK4196","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644760228","title":"Guardant Health director Tariq Musa disposes of 116 common shares for $15,102.04","url":"https://stock-news.laohu8.com/highlight/detail?id=2644760228","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644760228?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:38","pubTimestamp":1781642321,"startTime":"0","endTime":"0","summary":"Guardant Health director Tariq Musa sold 116 shares on June 16, 2026 at USD 130.19.He also received 250 shares on June 15, 2026 from the vesting of Restricted Stock Units at USD 0.Musa ended with 8,796 shares of common stock.He held 2,249 Restricted Stock Units following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDLHQlvT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health director Tariq Musa disposes of 116 common shares for $15,102.04","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","GH","BK4535","BK4588","BK4585","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643789207","title":"Guardant Health CIO Kumud Kalia sells 3,418 shares worth $445,156.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2643789207","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643789207?lang=en_us&edition=fundamental","pubTime":"2026-06-16 06:09","pubTimestamp":1781561385,"startTime":"0","endTime":"0","summary":"Guardant Health Chief Information Officer Kumud Kalia sold 3,418 common shares on June 11, 2026 at USD 130.24 each.Kalia’s direct holdings fell to 41,090 shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL3b3fxN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health CIO Kumud Kalia sells 3,418 shares worth $445,156.57","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4551","BK4196","BK4535","GH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643240821","title":"Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643240821","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643240821?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:30","pubTimestamp":1781469000,"startTime":"0","endTime":"0","summary":"Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH New resul","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/14/3311470/0/en/Crinetics-Presents-Full-Results-From-Phase-2-Trial-of-Atumelnant-in-Congenital-Adrenal-Hyperplasia-CAH-in-Oral-Presentation-at-ENDO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4183","LU0072461881.USD","BK4588","BK4535","BK4175","BK4551","LU1880398471.USD","LU0052756011.USD","GH","LU1983299246.USD","BK4196","LU0310799852.SGD","LU0211327993.USD","LU1267930227.SGD","BK4585","LU0310800965.SGD","CAH","SG9999001440.SGD","LU0006061336.USD","LU0792757196.USD","LU1571399168.USD","LU1880398554.USD","LU0211328371.USD","LU0128525689.USD","LU0154236417.USD","LU1267930490.SGD","LU0889566641.SGD","LU0162691827.USD","LU1267930813.SGD","ENDO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643478322","title":"Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control","url":"https://stock-news.laohu8.com/highlight/detail?id=2643478322","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643478322?lang=en_us&edition=fundamental","pubTime":"2026-06-15 02:45","pubTimestamp":1781462700,"startTime":"0","endTime":"0","summary":"Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms Treatment also resulted in stable or r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/14/3311468/0/en/Crinetics-Presents-Long-Term-Data-at-ENDO-2026-Confirming-PALSONIFY-paltusotine-Provides-Durable-Consistent-Acromegaly-Control.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENDO","GH","BK4183","BK4588","BK4585","ASD","PTH","BK4196","BK4551","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643186452","title":"Guardant Health CIO Kumud Kalia sells 5,000 common shares worth $652,030.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2643186452","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643186452?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:27","pubTimestamp":1781296063,"startTime":"0","endTime":"0","summary":"Guardant Health CIO Kumud Kalia sold 5,000 common shares on June 10 at USD 130.41.Direct holdings fell to 44,508 shares following the sale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL7WjK9T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health CIO Kumud Kalia sells 5,000 common shares worth $652,030.00","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","GH","BK4196","BK4588","BK4551","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642732299","title":"Guardant Health Set to Benefit From Genomic Profiling Growth, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2642732299","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642732299?lang=en_us&edition=fundamental","pubTime":"2026-06-12 23:03","pubTimestamp":1781276637,"startTime":"0","endTime":"0","summary":"Guardant Health  is positioned to benefit from growth opportunities in tumor profiling business, RBC Capital Markets said in a Thursday report.The report said its core tumor profiling business is vastly underpenetrated, with a recent study found only about 25% of metastatic cancer patients in the US receive genomic profiling.\"Guardant, as the market leader, is best positioned to benefit as adoption expands,\" the report said.The recent approval of Guardant360 Liquid CDx should unlock a meaningful volume opportunity, while growing use of Guardant Reveal for therapy response monitoring should have positive knock-on effects for G360 demand, the report said.The note also pointed to other catalysts, including pending Medicare coverage decisions for Guardant Reveal.RBC initiated coverage on the stock with an outperform rating and a $185 price target.Price: 132.69, Change: +1.79, Percent Change: +1.37","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","GH","BK4196","BK4588","BK4585","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642261448","title":"RBC Initiates Guardant Health at Outperform With $185 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2642261448","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642261448?lang=en_us&edition=fundamental","pubTime":"2026-06-12 17:52","pubTimestamp":1781257926,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $143.23, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","BK4196","BK4535","GH","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642268681","title":"U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle","url":"https://stock-news.laohu8.com/highlight/detail?id=2642268681","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642268681?lang=en_us&edition=fundamental","pubTime":"2026-06-12 15:34","pubTimestamp":1781249644,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, OracleJune 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nL4N42K0GE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CASY","AMDS","AMDG","JBL","REG","MGM","CVNX","MKTX","OCFC","AROW","SUNB","AVTX","HQY","QCOM","GH","AMDW","DAN","SMCI","BSX","DASH","ETSY","ORCU","ORCL","AMDL","FULT","QCMU","FDX","PHIN","ADBG","AMUU","RH","ANET","BFH","KTOS","AMD","CDE","FTNT","ADBE","AMDY","CASS","MFIN","IVT","AMDU","SAIL","NTRA","SMYY","PEP","CVNA","RHP","CSCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642251415","title":"Guardant Health Inc : RBC Initiates Coverage With Outperform Rating; Target Price $185","url":"https://stock-news.laohu8.com/highlight/detail?id=2642251415","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642251415?lang=en_us&edition=fundamental","pubTime":"2026-06-12 12:26","pubTimestamp":1781238385,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nFWN42J0R5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","BK4585","BK4535","BK4551","GH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.guardanthealth.com","stockEarnings":[{"period":"1week","weight":0.0608},{"period":"1month","weight":0.1514},{"period":"3month","weight":0.5546},{"period":"6month","weight":0.33},{"period":"1year","weight":1.7397},{"period":"ytd","weight":0.3409}],"compareEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":-0.0166},{"period":"3month","weight":0.1366},{"period":"6month","weight":0.0622},{"period":"1year","weight":0.2084},{"period":"ytd","weight":0.0753}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.071093},{"month":2,"riseRate":0.25,"avgChangeRate":0.034152},{"month":3,"riseRate":0.5,"avgChangeRate":-0.022808},{"month":4,"riseRate":0.375,"avgChangeRate":-0.022604},{"month":5,"riseRate":0.625,"avgChangeRate":0.118443},{"month":6,"riseRate":0.75,"avgChangeRate":0.078664},{"month":7,"riseRate":0.714286,"avgChangeRate":0.051469},{"month":8,"riseRate":0.571429,"avgChangeRate":0.08346},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.065825},{"month":10,"riseRate":0.285714,"avgChangeRate":0.030366},{"month":11,"riseRate":0.75,"avgChangeRate":0.130427},{"month":12,"riseRate":0.5,"avgChangeRate":-0.066498}],"exchange":"NASDAQ","name":"Guardant Health Inc.","nameEN":"Guardant Health Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Guardant Health Inc.,GH,Guardant Health Inc.股票,Guardant Health Inc.股票老虎,Guardant Health Inc.股票老虎国际,Guardant Health Inc.行情,Guardant Health Inc.股票行情,Guardant Health Inc.股价,Guardant Health Inc.股市,Guardant Health Inc.股票价格,Guardant Health Inc.股票交易,Guardant Health Inc.股票购买,Guardant Health Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}